In vivo noninvasive preclinical tumor hypoxia imaging methods: a review

被引:13
作者
D'Alonzo, Rebecca A. [1 ]
Gill, Suki [1 ,2 ]
Rowshanfarzad, Pejman [1 ]
Keam, Synat [3 ]
MacKinnon, Kelly M. [1 ]
Cook, Alistair M. [3 ]
Ebert, Martin A. [1 ,2 ,4 ]
机构
[1] Univ Western Australia, Sch Phys Math & Comp, Crawley, Australia
[2] Sir Charles Gairdner Hosp, Dept Radiat Oncol, Nedlands, WA, Australia
[3] Univ Western Australia, Sch Med, Crawley, Australia
[4] 5D Clin, Claremont, Australia
关键词
Cancer; tumor; hypoxia; microenvironment; imaging; preclinical; ELECTRON-PARAMAGNETIC-RESONANCE; CARBONIC-ANHYDRASE-IX; MAGNETIC-RESONANCE; PHOTOACOUSTIC MICROSCOPY; COMPUTED-TOMOGRAPHY; BLOOD OXYGENATION; ENHANCED MRI; PERFUSION CT; PET; CANCER;
D O I
10.1080/09553002.2021.1900943
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Tumors exhibit areas of decreased oxygenation due to malformed blood vessels. This low oxygen concentration decreases the effectiveness of radiation therapy, and the resulting poor perfusion can prevent drugs from reaching areas of the tumor. Tumor hypoxia is associated with poorer prognosis and disease progression, and is therefore of interest to preclinical researchers. Although there are multiple different ways to measure tumor hypoxia and related factors, there is no standard for quantifying spatial and temporal tumor hypoxia distributions in preclinical research or in the clinic. This review compares imaging methods utilized for the purpose of assessing spatio-temporal patterns of hypoxia in the preclinical setting. Imaging methods provide varying levels of spatial and temporal resolution regarding different aspects of hypoxia, and with varying advantages and disadvantages. The choice of modality requires consideration of the specific experimental model, the nature of the required characterization and the availability of complementary modalities as well as immunohistochemistry.
引用
收藏
页码:593 / 631
页数:39
相关论文
共 332 条
[1]  
Abolmaali, 2010, LUNG CANCER, V70
[2]   Theory, Instrumentation, and Applications of Electron Paramagnetic Resonance Oximetry [J].
Ahmad, Rizwan ;
Kuppusamy, Periannan .
CHEMICAL REVIEWS, 2010, 110 (05) :3212-3236
[3]  
Akhlaghi M., 2009, ACTA PHARMACEUT, V59
[4]   Synthesis and biological evaluation of a 99mTc-labelled sulfonamide conjugate for in vivo visualization of carbonic anhydrase IX expression in tumor hypoxia [J].
Akurathi, Vamsidhar ;
Dubois, Ludwig ;
Lieuwes, Natasja G. ;
Chitneni, Satish K. ;
Cleynhens, Bernard J. ;
Vullo, Daniela ;
Supuran, Claudiu T. ;
Verbruggen, Alfons M. ;
Lambin, Philippe ;
Bormans, Guy M. .
NUCLEAR MEDICINE AND BIOLOGY, 2010, 37 (05) :557-564
[5]   Correlation of magnetic resonance and oxygen microelectrode measurements of carbogen-induced changes in tumor oxygenation [J].
Al-Hallaq, HA ;
River, JN ;
Zamora, M ;
Oikawa, H ;
Karczmar, GS .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 41 (01) :151-159
[6]   Hyperpolarized 13C Lactate, Pyruvate, and Alanine: Noninvasive Biomarkers for Prostate Cancer Detection and Grading [J].
Albers, Mark J. ;
Bok, Robert ;
Chen, Albert P. ;
Cunningham, Charles H. ;
Zierhut, Matt L. ;
Zhang, Vickie Yi ;
Kohler, Susan J. ;
Tropp, James ;
Hurd, Ralph E. ;
Yen, Yi-Fen ;
Nelson, Sarah J. ;
Vigneron, Daniel B. ;
Kurhanewicz, John .
CANCER RESEARCH, 2008, 68 (20) :8607-8615
[7]  
Ale A, 2012, NAT METHODS, V9, P615, DOI [10.1038/NMETH.2014, 10.1038/nmeth.2014]
[8]   Comparison of Optical and Power Doppler Ultrasound Imaging for Non-Invasive Evaluation of Arsenic Trioxide as a Vascular Disrupting Agent in Tumors [J].
Alhasan, Mustafa K. ;
Liu, Li ;
Lewis, Matthew A. ;
Magnusson, Jennifer ;
Mason, Ralph P. .
PLOS ONE, 2012, 7 (09)
[9]   Facilitating Tumor Functional Assessment by Spatially Relating 3D Tumor Histology and In Vivo MRI: Image Registration Approach [J].
Alic, Lejla ;
Haeck, Joost C. ;
Bol, Karin ;
Klein, Stefan ;
van Tiel, Sandra T. ;
Wielepolski, Piotr A. ;
de Jong, Marion ;
Niessen, Wiro J. ;
Bernsen, Monique ;
Veenland, Jifke F. .
PLOS ONE, 2011, 6 (08)
[10]   Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate [J].
Anderson, HL ;
Yap, JT ;
Miller, MP ;
Robbins, A ;
Jones, T ;
Price, PM .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) :2823-2830